title: The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
abstract: Isoniazid preventive therapy (IPT) is recommended in patients on antiretroviral treatment. Isoniazid (INH) inhibits CYP3A4, which metabolises nevirapine (NVP). Administration of INH may cause higher NVP concentrations and toxicity. We studied the effect of INH on NVP concentrations  in 21 patients randomised to either placebo (n = 13) or INH (n = 8) in an ongoing trial of IPT in patients on ART. INH was associated with a 24% increase in median NVP area under the plasma concentration-time curve for the 12 h dosing interval, which was not statistically significant  (P = 0.66).
authors: Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital University of Cape Town, Cape Town, South Africa.
authors: E H
authors: EH
authors: Decloedt
authors: J
authors: J
authors: Mwansa-Kambafwile
authors: J-S
authors: JS
authors: van der Walt
authors: H
authors: H
authors: McIlleron
authors: P
authors: P
authors: Denti
authors: P
authors: P
authors: Smith
authors: L
authors: L
authors: Wiesner
authors: M
authors: M
authors: Rangaka
authors: R J
authors: RJ
authors: Wilkinson
authors: G
authors: G
authors: Maartens
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000995:Antitubercular Agents / Q000008:administration & dosage*; D019540:Area Under Curve; D001711:Biotransformation; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D004334:Drug Administration Schedule; D004347:Drug Interactions; D016903:Drug Monitoring; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013019:South Africa
chemical_list: D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D019829:Nevirapine; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D007538:Isoniazid